So Calidi Biotherapeutics just wrapped up their $5.2M public offering last month - 10.52 million units at $0.50 each. What caught my attention is the warrant structure they're using. They've got multiple series of stock warrants attached (6-month, 12-month, and 5-year options), which is pretty standard for biotech fundraising but gives investors a lot of flexibility to capture upside if things move.

The interesting part? They also amended existing warrants held by previous investors, bringing those exercise prices down to $0.50 to match the new offering. That's a pretty significant move - basically rewarding early backers while keeping everyone on the same playing field going forward.

As for what they're actually doing with the cash - it's working capital and general corporate purposes, which is vague but typical. Their lead candidate CLD-401 is targeting lung and head/neck cancers, still in IND-enabling studies. The stock tanked 53% when this priced though, which honestly isn't shocking. Biotech offerings tend to pressure the stock short-term, especially when you're diluting with this many new stock warrants and units.

Ladenburg Thalmann managed the deal. Worth watching how this plays out - the warrant holders have some decent runway to see if the platform actually delivers on its promise.